Trial Details
Not RecruitingBasic Information
| Clinical ID | c3358 |
|---|---|
| Identifier | ACTRN12606000240549 |
| Trial Title | Phase Ib Chronic Pharmacokinetic and Tolerability Study of Oral NV-52 in Normal Healthy Volunteers |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Healthy Volunteers; Healthy Volunteers;Other - Research that is not of generic health relevance and not applicable to specific health categories listed above |
| Interventions | NV-52 is an experimental drug which is being developed as an orally-delivered non-toxic agent being developed for the maintenance of remission in inflammatory bowel disease (IBD). The duration of intervention is 10 days at a dose of 400 mg per day with no control group. |
Participant Information
| Sponsor | Novogen Research Pty Limited |
|---|---|
| City | - |
| Country/Region | Australia |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE1 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |